

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 April 2001 (26.04.2001)

PCT

(10) International Publication Number
WO 01/29082 A1

(51) International Patent Classification⁷: C07K 14/47,
14/72

(21) International Application Number: PCT/FI00/00913

(22) International Filing Date: 20 October 2000 (20.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/422,985 22 October 1999 (22.10.1999) US

(71) Applicant (*for all designated States except US*): OY JUVANTIA PHARMA LTD [FI/FI]; Tykistökatu 6 A, FIN-20520 Turku (FI).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SNAPIR, Amir [IL/FI]; Ritzinkuja 1 K 63, FIN-20380 Turku (FI). HEINONEN, Paula [FI/FI]; Puutarhakatu 6 A 10, FIN-20100 Turku (FI). ALHOPURO, Pia [FI/FI]; Sirkkalankatu 6 C 35, FIN-20520 Turku (FI). KARVONEN, Matti [FI/FI]; Sirkkalankatu 16 A a 7, FIN-20500 Turku (FI). KOULU, Markku [FI/FI]; Kotikatu 4 B 8, FIN-20700 Turku (FI). PESONEN, Ullamari [FI/FI]; Luodikkokuja 6, FIN-20900 Turku (FI). SCHEININ, Mika [FI/FI]; Mannerheiminkatu 23, FIN-21100 Naantali

(FI). SALONEN, Jukka, T. [FI/FI]; Karjalanharjunniementie 68, FIN-70940 Jännevirta (FI). TUOMAINEN, Tomi-Pekka [FI/FI]; Orsitie 3 F 15, FIN-70820 Kuopio (FI). LAKKA, Timo, A. [FI/FI]; Kuntokuja 6 A 1, FIN-70200 Kuopio (FI). NYSSÖNEN, Kristiina [FI/FI]; Rinnekatu 2-4 B 17, FIN-70600 Kuopio (FI). SALONEN, Riitta [FI/FI]; Karjalanharjunniementie 68, FIN-70940 Jännevirta (FI). KAUKHANEN, Jussi [FI/FI]; Lehtikuusikontie 3 B 6, FIN-70620 Kuopio (FI). VALKONEN, Veli-Pekka [FI/FI]; Kaartokatu 17 C 32, FIN-70620 Kuopio (FI).

(74) Agent: TURUN PATENTTITOIMISTO OY; P.O. Box 99, FIN-20521 Turku (FI).

(81) Designated States (*national*): CA, IN, JP, US, ZA.

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A DNA MOLECULE ENCODING A VARIANT α_{2B} -ADRENOCEPTOR PROTEIN, AND USES THEREOF

(57) Abstract: This invention relates to a DNA sequence comprising a nucleotide sequence encoding a variant α_{2B} -adrenoceptor protein and to said variant α_{2B} -adrenoceptor protein as well as a method for screening a subject to determine if said subject is a carrier of a variant gene that encodes said variant α_{2B} -adrenoceptor. Further this invention relates to a method for treating a mammal suffering from vascular contraction of coronary arteries, said method comprising the step of administering a selective α_{2B} -adrenoceptor antagonist to said mammal and to transgenic animals comprising a human DNA molecule encoding human α_{2B} -adrenoceptor or said variant α_{2B} -adrenoceptor.

WO 01/29082 A1

A DNA MOLECULE ENCODING A VARIANT α_{2B} -ADRENOCEPTOR PROTEIN, AND USES THEREOF

FIELD OF THE INVENTION

This invention relates to a DNA molecule encoding a variant human α_{2B} -adreno-
5 ceptor, said variant α_{2B} -adrenoceptor protein and a method to assess the risk of individuals to suffer from vascular contraction of coronary arteries in mammals as well as a method for the treatment of vascular contraction of coronary arteries. This invention also relates to transgenic animals comprising a human DNA molecule encoding human α_{2B} -adrenoceptor or said variant α_{2B} -adrenoceptor.

10 BACKGROUND OF THE INVENTION

The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference.

The α_2 -adrenoceptors (α_2 -ARs) mediate many of the physiological effects of the
15 catecholamines norepinephrine and epinephrine. Three genetic subtypes of α_2 -adrenoceptors are known in humans and other mammals, denoted as α_{2A} -, α_{2B} - and α_{2C} -adrenoceptors. The human genes encoding the receptors are located on chromosomes 10, 2 and 4, respectively. No splice variants are known to exist of these receptors, as the genes are intronless. The tissue distributions and
20 physiological and pharmacological functions of the receptor subtypes have been reviewed e.g. by MacDonald et al. (1997) and Docherty (1998). Based on recent studies with gene-targeted and transgenic mice, α_{2A} -adrenoceptors mediate most of

the pharmacological actions ascribed to currently available α_2 -adrenoceptor agonists, including inhibition of neurotransmitter release, central hypotensive and bradycardic effects, sedation and anesthesia, and analgesia. The same studies indicate that α_{2B} -adrenoceptors mediate peripheral vasoconstriction in response to
5 agonist activation (Link et al. 1996, Macmillan et al. 1996). Other physiological or pharmacological effects have not been associated with certainty with this receptor subtype. The α_{2C} -adrenoceptor subtype appears to be involved in regulation of complex behaviors. It is not known that this subtype would have important functions in peripheral tissues outside the central nervous system or in cardiovascular
10 regulation.

Coronary heart disease (CHD), like many other common disorders, arises from complex interactions between genetic and environmental factors. It is reasonable to assume that functionally important genetic variation in mechanisms important for the regulation of vascular functions, including the coronary vasculature, will be
15 found to be associated with the pathogenesis and therapy of CHD. A variant form of the human α_{2B} -AR gene was recently identified (Heinonen et al., 1999). The variant allele encodes a receptor protein with a deletion of three glutamate residues in an acidic stretch of 18 amino acids (of which 15 are glutamates) located in the third intracellular loop of the receptor polypeptide. This acidic stretch is a unique feature
20 in the primary structure of α_{2B} -AR in comparison to α_{2A} -AR and α_{2C} -AR, suggesting that the motif has a distinct role in the function of α_{2B} -AR. Amino acid sequence alignment of α_{2B} -AR polypeptides of different mammals reveals that the acidic stretch is highly conserved among the α_{2B} -ARs of mammals and that the acidic stretch is long in humans in comparison to other species. This suggests that
25 the motif is important for the functionality of the receptor, and that the short form (D for "deletion") probably represents the ancestral form and the long form (I for "insertion") could well represent a more recent allelic variant in humans. Jewell-Motz and Liggett (1995) studied the *in vitro* functions of this stretch using site-

directed mutagenesis to delete as well as to substitute 16 amino acids of the stretch. Their results suggest that this acidic motif is necessary for full agonist-promoted receptor phosphorylation and desensitization.

5 Based on the vasoconstrictive property of α_{2B} -AR in mice and the involvement of this acidic region in the desensitization mechanism of the receptor, we hypothesized that the deletion variant confers reduced receptor desensitization and therefore augmented vasoconstriction that could be associated with cardiovascular pathologies. To test this hypothesis, we carried out a 4-year prospective study in 912 middle-aged Finnish men.

10 OBJECT AND SUMMARY OF THE INVENTION

One object of this invention is to provide a DNA sequence of a variant human α_{2B} -adrenoceptor gene and the corresponding variant α_{2B} -adrenoceptor protein.

15 Another object of the invention is to provide a method for screening a subject to assess if an individual is at risk to suffer from vascular contraction of coronary arteries.

A third object of the invention is to provide a method for the treatment of vascular contraction of coronary arteries of mammals.

A fourth object of the invention is to provide a transgenic animal with a gene encoding a human α_{2B} -adrenoceptor or said variant thereof.

20 Thus, according to one aspect the invention concerns a DNA sequence comprising a nucleotide sequence encoding a variant α_{2B} -adrenoceptor protein with a deletion of at least 1 glutamate from a glutamic acid repeat element of 12 glutamates, amino

acids 298–309, in an acidic stretch of 18 amino acids 294–311, located in the 3rd intracellular loop of the receptor polypeptide.

The invention further concerns a variant α_{2B} -adrenoceptor protein with a deletion of at least 1 glutamate from a glutamic acid repeat element of 12 glutamates, amino
5 acids 298–309, in an acidic stretch of 18 amino acids 294–311, located in the 3rd intracellular loop of the receptor polypeptide.

According to another aspect the invention concerns a method for screening a subject to determine if said subject is a carrier of a said variant gene with both alleles encoding a said variant α_{2B} -adrenoceptor, i.e. to determine if said subject's genotype
10 of the human α_{2B} -adrenoceptor is of the deletion/deletion (D/D) type, comprising the steps of

- a) providing a biological sample of the subject to be screened,
- b) providing an assay for detecting in the biological sample the presence of
 - i) the insertion/insertion (I/I) or deletion/insertion (D/I) genotypes of the
15 human α_{2B} -adrenoceptor, or
 - ii) the D/D genotype of the human α_{2B} -adrenoceptor, and
- c) assessing at least one of the two following
 - i) an individual's risk to develop a disease involving vascular contraction of coronary arteries, or
 - 20 ii) an individual's need for α_{2B} -selective or α_{2B} -nonselective α_2 -adrenoceptor antagonist therapy,

based on whether said subject is of said D/D genotype or not.

According to a third aspect the present invention concerns a method for treating a mammal suffering from vascular contraction of coronary arteries, said method

comprising the step of administering a selective α_{2B} -adrenoceptor antagonist to said mammal.

According to a fourth aspect the present invention concerns a transgenic animal which carries a human DNA sequence comprising a nucleotide sequence encoding a
5 human α_{2B} -adrenoceptor protein or a variant thereof.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a DNA molecule encoding a variant human α_{2B} -adrenoceptor, said variant α_{2B} -adrenoceptor protein and a method to assess the risk of individuals to suffer from vascular contraction of coronary arteries in
10 mammals as well as a method for the treatment of vascular contraction of coronary arteries. The present invention also relates to transgenic animals comprising a human DNA molecule encoding a human α_{2B} -adrenoceptor or said variant α_{2B} -adrenoceptor protein.

The word treating shall also be understood to include preventing.

15 The concept "a deletion of at least 1 glutamate from a glutamic acid repeat element of 12 glutamates" refers to any deletion of 1 to 12 glutamates irrespective of the specific location in, or how many glutamates from said repeat element of 12 glutamates, amino acids 298–309 (SEQ ID NO: 4), in an acidic stretch of 18 amino acids 294–311 located in the 3rd intracellular loop of the receptor
20 polypeptide are deleted.

The concept "deletion/deletion (D/D) genotype of the human α_{2B} -adrenoceptor", in short "D/D genotype", refers to a genotype of an individual having both α_{2B} -adrenoceptor alleles code for a variant α_{2B} -adrenoceptor with a deletion of at least 1 glutamate from a glutamic acid repeat element of 12 glutamates, amino

acids 298–309, in an acidic stretch of 18 amino acids 294–311 (SEQ ID NO: 4), located in the 3rd intracellular loop of the receptor polypeptide. Correspondingly "deletion/insertion (D/I) genotype" refers to a genotype having one of the gene alleles code for an α_{2B} -adrenoceptor with a said deletion and the other without a said deletion, i.e. with a respective insertion, and thus the "insertion/insertion (I/I) genotype" refers to a genotype having both alleles code for an α_{2B} -adrenoceptor without said deletion or deletions.

We recently identified a common variant form (SEQ ID NO: 1) of the human α_{2B} -AR gene (SEQ ID NO: 3). This variant gene encodes a receptor protein (SEQ ID NO: 2) with a deletion of 3 glutamates, amino acids 307-309, from a glutamic acid (Glu) repeat element of 12 glutamates, amino acids 298–309, in an acidic stretch of 18 amino acids 294–311 (SEQ ID NO: 4), located in the 3rd intracellular loop of the receptor polypeptide. This variant gene (SEQ ID NO: 1) was associated with decreased basal metabolic rate (BMR) in a group of obese Finnish subjects (Heinonen et al. 1999). Of the 166 obese subjects, 47 (28 %) were homozygous for the long 12 glutamate repeat element (Glu¹²/Glu¹²), whereas 90 (54 %) were heterozygous (Glu¹²/Glu⁹) and 29 (17 %) were homozygous for the short form (Glu⁹/Glu⁹).

The results to be presented below show that in a population-based cohort of 912 Finnish middle-aged men subjects homozygous for the short form (Glu⁹/Glu⁹) described above, thus representing a deletion/deletion (D/D) genotype of the α_{2B} -adrenoceptor, have a significantly elevated risk for acute coronary events in a four-year follow-up study. The risk for an acute coronary event, defined as definite or possible acute myocardial infarction (AMI) or prolonged (>20 min) chest pain requiring hospitalization, was increased 2.5 fold in subjects who had this D/D genotype. This increase in the risk for acute coronary events is as great as so far observed for any other genetic risk factor for acute coronary events or acute

myocardial infarction in a prospective population study. Also the frequency of a study subject having a history of coronary heart disease (CHD) as well as CHD in an exercise test was associated with this D/D genotype. Based on these results and previous publications referred to above it can be postulated that this D/D genotype is
5 related to an impaired capacity to downregulate α_{2B} -adrenoceptor function during sustained receptor activation. Since altered α_{2B} -adrenoceptor function seems to be of relevance in the pathogenesis of a significant fraction of all cases of acute coronary events in subjects with this D/D genotype (homozygous Glu⁹/Glu⁹) we believe it could also be of relevance in subjects with the insertion/deletion (I/D)
10 (heterozygous Glu¹²/Glu⁹) and insertion/insertion (I/I) (homozygous Glu¹²/Glu¹²) genotypes when other risk factors for AMI are present. Further, since this specific deletion of 3 glutamates, amino acids 307-309, from said glutamic acid repeat element of 12 glutamates, amino acids 298-309, in said acidic stretch of 18 amino acids 294-311, located in the 3rd intracellular loop of the receptor polypeptide seems
15 to be of relevance in cases of AMI we believe that also other deletions, i.e. deletions of at least 1 glutamate, from said glutamic acid repeat element of 12 glutamates, amino acids 298-309, could be of relevance in the pathogenesis of AMI, because the 3rd intracellular loop of the receptor polypeptide it is located in seems to have an essential role in the downregulation of the α_{2B} -adrenoceptor.

20 Thus based on the results to be presented below and the publications referred to above an α_{2B} -adrenoceptor antagonist would be useful for treating a mammal suffering from vascular contraction of coronary arteries.

Furthermore, an α_{2B} -adrenoceptor antagonist selective for the α_{2B} -adrenoceptor subtype would be therapeutically beneficial for the treatment of a disease involving
25 said vascular contraction of coronary arteries. Such a disease could be clinically expressed as chronic angina pectoris, specifically e.g. AMI, unstable angina pectoris or Prinzmetal's variant form of angina pectoris. If α_{2B} -adrenoceptor dependent

- vasoconstriction is a causative factor in some cases of AMI, then antagonism of these receptors should restore coronary circulation and reduce the ischemic myocardial damage. An α_{2B} -adrenoceptor antagonist will relieve the vasoconstrictive component in the sustained ischemic episode of unstable angina pectoris, thus alleviating the symptoms and preventing AMI. Vasoconstriction is a key factor in the pathogenesis of Prinzmetal's angina, and an α_{2B} -adrenoceptor antagonist may resolve and prevent attacks. An α_{2B} -adrenoceptor antagonist will help to alleviate the vasoconstrictive component in all types of CHD, providing both symptomatic relief and protection from AMI.
- 10 α_{2B} -adrenoceptors mediate vascular contraction of coronary arteries, and genetic polymorphism present in the α_{2B} -adrenoceptor gene renders some subjects more susceptible to α_{2B} -adrenoceptor mediated vasoconstriction of coronary arteries and associated clinical disorders. These subjects will especially benefit from treatment with an α_{2B} -adrenoceptor antagonist, and will be at increased risk for adverse effects
- 15 if subtype-nonselective α_2 -agonists are administered to them. Therefore, a gene test recognizing subjects with a deletion variant of the α_{2B} -adrenoceptor gene will be useful in diagnostics and patient selection for specific therapeutic procedures. A gene test recognizing the D/D genotype of the α_{2B} -adrenoceptor is useful in assessing an individual's risk to develop AMI and other clinical disorders involving
- 20 vascular contraction of coronary arteries related to the D/D genotype. A gene test recognizing the D/D genotype of the α_{2B} -adrenoceptor is useful in selecting drug therapy for patients with diseases involving vascular contraction of coronary arteries associated with the D/D genotype; subjects with the D/D genotype will especially benefit from therapy with α_2 -adrenoceptor antagonists (α_{2B} -selective or
- 25 nonselective). A gene test recognizing the D/D genotype of the α_{2B} -adrenoceptor is useful in selecting drug therapy for patients who might be at increased risk for adverse effects of α_2 -adrenergic agonists; either, it will be possible to avoid the use

of α_2 -agonists in such patients, or it will be possible to include a specific α_{2B} -antagonist in their therapeutic regimen.

The DNA sequence can be used for screening a subject to determine if said subject is a carrier of a variant gene. The determination can be carried out either as a DNA
5 analysis according to well known methods, which include direct DNA sequencing of the normal and variant gene, allele specific amplification using the polymerase chain reaction (PCR) enabling detection of either normal or variant sequence, or by indirect detection of the normal or variant gene by various molecular biology methods including e.g. PCR-single stranded conformation polymorphism (SSCP)
10 method or denaturing gradient gel electrophoresis (DGGE). Determination of the normal or variant gene can also be done by using a restriction fragment length polymorphism (RFLP) method, which is particularly suitable for genotyping large numbers of samples. Similarly, a test based on gene chip technology can be easily developed in analogy with many currently existing such tests for single-nucleotide
15 polymorphisms. Thus such an test could be an assay carried out using a gene chip, microarray, strip, panel or similar combination of more than one genes, mutations or RNA expressions to be assayed.

The determination can also be carried out at the level of RNA by analyzing RNA expressed at tissue level using various methods. Allele specific probes can be
20 designed for hybridization. Hybridization can be done e.g. using Northern blot, RNase protection assay or in situ hybridization methods. RNA derived from the normal or variant gene can also be analyzed by converting tissue RNA first to cDNA and thereafter amplifying cDNA by an allele specific PCR method.

As examples of useful α_{2B} -adrenoceptor antagonists can be mentioned imiloxan
25 [2-(1-ethyl-2-imidazolyl)methyl-1,4-benzodioxan, ARC-239 [2-[2-(4-(2-methoxy-phenyl)piperazin-1-yl)ethyl]-4,4-dimethyl-1,3-(2H,4H)-isoquinolindione], prazosin

[1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine] and chlorpromazine [2-chloro-N,N-dimethyl-10H-phenothiazine-10-propanamine].

The required dosage of the compounds will vary with the particular condition being treated, the severity of the condition, the duration of the treatment, the administration route and the specific compound being employed. A typical therapeutically effective daily dose administered, e.g. orally or by infusion, can vary from e.g. 0.1 µg to 10 mg per kilogram body weight of an adult person.

Influence of the variant gene sequence can be investigated in transgenic animals. A transgenic animal can be generated e.g. using targeted homologous recombination methodology. This will provide an ideal preclinical model to investigate and screen new drug molecules, which are designed to modify the influence of the variant gene.

The invention will be described in more detail in the experimental section.

EXPERIMENTAL SECTION

Determination of genomic alleles encoding the α_{2B} -adrenoceptor

15 *PCR-SSCA analysis*

The polymerase chain reaction-single stranded conformational analysis (PCR-SSCA) used to identify the genomic alleles encoding the α_{2B} -adrenoceptor was carried out as follows: The genomic DNA encoding the α_{2B} -adrenergic receptor was amplified in two parts specific for the intronless α_{2B} -adrenoceptor gene sequence (Lomasney et al. 1990). The PCR primer pairs for PCR amplification were as follows: Pair 1: 5'-GGGGCGACGCTCTTGTCTA-3' (SEQ ID NO: 5) and 5'-GGTCTCCCCCTCCTCCTTC-3' (SEQ ID NO: 6) (product size 878 bp),

pair 2: 5'-GCAGCAACCGCAGAGGTC-3' (SEQ ID NO: 7) and 5'-GGGCAA-GAAGCAGGGGTGAC-3' (SEQ ID NO: 8) (product size 814 bp). The primers were delivered by KeboLab (Helsinki, Finland). PCR amplification was conducted in a 5 µl volume containing 100 ng genomic DNA (isolated from whole blood), 2.5 mmol/l of each primer, 1.0 mmol/l deoxy-NTPs, 30 nmol/l ³³P-dCTP and 0.25 U AmpliTaq DNA polymerase (Perkin Elmer Cetus, Norwalk, CT). PCR conditions were optimized using the PCR OptimizerTM kit (Invitrogen, San Diego, CA). Samples were amplified with a GeneAmp PCR System 9600 (Perkin Elmer Cetus). PCR products were digested with restriction enzymes for SSCA analysis. The product of primer pair 1 was digested with Dde I and Dra III (Promega Corp., Madison, WI). The product of primer pair 2 was digested with Alu I and Hinc II (Promega Corp.). The digested samples were mixed with SSCA buffer containing 95 % formamide, 10 mmol/l NaOH, 0.05 % xylene cyanol and 0.05 % bromophenol blue (total volume 25 µl). Before loading, the samples were denatured for 5 min at 95 °C and kept 5 min on ice. Three microliters of each sample were loaded on MDETM high-resolution gel (FMC, BioProducts, Rockland, MA). The gel electrophoresis was performed twice, at two different running conditions: 6 % MDE gel at +4 °C and 3 % MDE gel at room temperature, both at 4 W constant power for 16 h. The gels were dried and autoradiography was performed by apposing to Kodak BioMax MR film for 24 h at room temperature.

Sequencing and genotyping

DNA samples migrating at different rates in SSCA were sequenced with the Thermo SequenaseTM Cycle Sequencing Kit (Amersham Life Science, Cleveland, OH).

For genotyping the identified 3-glutamic acid deletion, DNA was extracted from peripheral blood using standard methods. The α_{2B} -AR I/D genotype was determined by separating PCR-amplified DNA fragments with electrophoresis. Based on the

nature of the I/D variant, identification of the long and short alleles was achieved by their different electrophoretic migration rates due to their 9 bp size difference.

The region of interest was amplified using a sense primer 5'-AGGGTGTTTGTG-GGGCATCT-3' (SEQ ID NO: 9) and an anti-sense primer 5'-CAAGCTGAGGCC-
5 GGAGACACT-3' (SEQ ID NO: 10) (Oligold, Eurogentec, Belgium), yielding a product size of 112 bp for the long allele (I) and 103 bp for the short allele (D). PCR amplification was conducted in a 10 µL volume containing ~100 ng genomic DNA, 1x buffer G (Invitrogen, San Diego, CA, USA), 0.8 mM dNTPs, 0.3 µM of each primer and 0.25 units of AmpliTaq DNA polymerase (Perkin Elmer
10 Cetus, Norwalk, CT, USA). Samples were amplified with a GeneAmp PCR System 9600 (Perkin Elmer Cetus). After initial denaturation at 94 °C for 2 minutes, the samples were amplified over 35 cycles. PCR amplification conditions were 96 °C (40 s), 69 °C (30 s) and 72 °C (30 s) followed by final extension at 72 °C for 6 minutes. The PCR products representing the long and short alleles were identified
15 by two alternative methods.

- 1) The amplified samples were mixed with 4 µl of stop solution (Thermo SequenaseTM Cycle Sequencing kit), heated to 95 °C for 2 min, and loaded hot onto sequencing gels (Long RangerTM, FMC). The gels were dried and autoradiography was performed as previously described.
- 20 2) Separation of the amplified PCR products was performed with electrophoresis on a high-resolution 4 % Metaphor agarose gel (FMC Bioproducts, Rockland, Maine) and the bands were visualized by ethidium bromide staining. In both methods, the long (Glu¹²) and short (Glu⁹) alleles were identified based on their different electrophoretic migration rates.

Follow-up study

The above referred four-year follow-up study of 912 Finnish middle-aged men subjects including 192 subjects with a specific deletion/deletion (D/D) genotype of the α_{2B} -adrenoceptor is described in more detail in the following:

- 5 Knowing the vasoconstrictive property of α_{2B} -AR in mice and the possible involvement of the investigated acidic region in the desensitization mechanism of the receptor we hypothesized that the observed insertion/deletion allelic variation could be associated with cardiovascular pathologies such as AMI. To test this hypothesis, we carried out a four-year follow-up study in 912 middle-aged Finnish
10 men with no prior history of AMI. The study was carried out as part of the Kuopio Ischemic Heart Disease Risk Factor Study (KIHD), which is an ongoing population-based study designed to investigate risk factors for cardiovascular diseases and related outcomes in men from eastern Finland (Salonen 1988). This area is known for its homogenous population (Sajantila et al. 1996) and high
15 coronary morbidity and mortality rates (Keys 1980).

Of the 912 subjects, 192 (21 %) had the D/D genotype, 256 (28 %) had the I/I genotype and 464 (51 %) were heterozygous i.e. I/D. This genotype distribution is in Hardy-Weinberg equilibrium ($p = 0.46$).

- Of the 37 cases that had an acute coronary event during the follow-up, 18 were
20 classified as definite AMI, 12 as possible AMI and seven as prolonged chest pain. Among the subjects with the D/D genotype, 15 (8 %) had an acute coronary event during the follow-up time. The corresponding incidences for the I/I and the heterozygous genotypes i.e. I/D were 10 (4 %) and 12 (3 %). The observed cumulative incidence of acute coronary events differed significantly among the
25 different genotypes ($p = 0.008$). No significant difference in the cumulative incidence of acute coronary events was found between the I/D and the I/I genotypes

($p = 0.4$) (table 1). There was a significant difference (log-rank $p = 0.0045$) between the D/D subgroup and the other two genotypes combined in the cumulative event-free time in the Kaplan-Meier survival function, demonstrating that there is a consistently increased incidence of acute coronary events in the D/D subgroup.

- 5 The D/D genotype was associated with a 2.5 fold increased risk for an acute coronary event (95% CI = 1.3–4.8, $p = 0.006$) in comparison to the other two genotypes combined. The relative risk remained above 2 after adjustment for major CHD risk factors (table 2).

10 The D/D subgroup was not significantly different from the I/D + I/I subgroup in terms of many known major risk factors for CHD. From 87 variables in the study database only 5 were significantly different between the D/D and the I/D + I/I genotype subgroups: 1. there were more acute coronary events in the D/D subgroup (8 % vs. 3 %, $p = 0.006$), 2. history of CHD was more prevalent in the D/D subgroup (37 % vs. 29 %, $p = 0.043$), 3. the prevalence of CHD in exercise test
15 was higher in the D/D subgroup (30 % vs. 22 %, $p = 0.036$), 4. mean hemoglobin level was higher in the D/D subgroup (149.0 g/l vs. 146.8 g/l, $p = 0.005$) and 5. mean dietary cholesterol intake (4-days) was lower in the D/D subgroup (411.6 mg vs. 440.1 mg, $p = 0.033$) (table 3). The first four observed differences support our hypothesis that the D/D genotype confers reduced receptor
20 desensitization and therefore augmented vasoconstriction. This augmented vasoconstriction is the reason for the increased incidence of acute coronary events, the higher prevalence of CHD in exercise and history of CHD. We hypothesize that the increased level of hemoglobin is due to relative anoxia of tissues because of this augmented vasoconstriction.

- 25 To examine the possibility that the D/D genotype is a genetic marker for acute coronary events rather than a causative factor, we have searched the literature for known genetic risk factors for acute coronary events and AMI and their

chromosomal localization. All but one (Apo-B) are on different chromosomes than the α_{2B} -AR gene (chromosome 2) and the gene for Apo-B is neither in the physical nor the genetic vicinity of the α_{2B} -AR gene. Cox regression analysis revealed that the increased RR for acute coronary events in the D/D subgroup is not affected by the serum Apo-B concentration.

Taken together, the known biological properties of the α_{2B} -AR, the homogeneity of the Finnish population with its relatively high incidence of CHD, the study design, the relatively large representative study population and the clustering of the findings around one trait suggest that the D/D receptor allele is a causal genetic risk factor for acute coronary events.

Table 1: The cumulative incidence of acute coronary events among men with different genotypes of the α_{2B} -AR (p values are stated below)

Genotype		Events (% of men at risk)	Men at risk (% of all)
D/D	observed	15 (8)	192 (21)
	expected	7.8	
I/D	observed	12 (3)	464 (51)
	expected	18.8	
I/I	observed	10 (4)	256 (28)
	expected	10.4	
I/D + I/I	observed	22 (3)	720 (79)
	expected	29.2	
Total	observed	37 (4)	912 (100)

P values for the above table:

D/D vs. I/D vs. I/I p = 0.008
D/D vs. I/D p = 0.002
D/D vs. I/I p = 0.038
I/D vs. I/I p = 0.389
D/D vs. I/D + I/I p = 0.005

Table 2: Relative risk (RR) and its 95% confidence interval (CI) for an acute coronary event – a comparison of each of the genotypes with the other two combined. Results of a Cox regression model for 37 acute coronary events in a population sample of 912 subjects

Genotype	Events/men at risk	RR (95% CI)	Adjusted RR (95% CI)
		p	p
D/D	15/192	2.5 (1.3–4.8) 0.006	2.3 (1.2–4.5) 0.014
I/D	12/464	0.44 (0.2–0.9) 0.020	0.5 (0.2–1.0) 0.052
I/I	10/256	1.03 (0.5–2.1) 0.940	0.96 (0.5–2.0) 0.901

Adjustment was done for age, CHD in the family, high cholesterol in the family, hypertension and smoking

Table 3: List of all significant differences ($p < 0.05$) between the D/D and the I/D+I/I genotype subgroups among 87 variables in the study database

Variable	D/D	I/D + I/I	p
Acute coronary events [event/n (%)]	15/192 (8)	22/720 (3)	0.006
Ischemic findings in exercise test [case/n (%)]	57/192 (30)	160/720 (22)	0.036
History of CHD [case/n (%)]	71/192 (37)	209/720 (29)	0.043
Mean blood haemoglobin [g/L]	149.0	146.8	0.005
Mean 4 day dietary cholesterol intake [mg]	411.6	440.1	0.033

% = Percent of men at risk

It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for the specialist in the field that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive.

REFERENCES

- Docherty JR: Subtypes of functional α_1 - and α_2 -receptors. *Eur J Pharmacol* 1998;361:1-15
- Heinonen P, Koulu M, Pesonen U, Karvonen M, Rissanen A, Laakso M, Valve R,
5 Uusitupa M, Scheinin M: Identification of a three amino acid deletion in the alpha-2B-adrenergic receptor which is associated with reduced basal metabolic rate in obese subjects. *J Clin Endocrinol Metab* 1999;84:2429-2433
- Jewell-Motz E, Liggett SB: An acidic motif within the third intracellular loop of the alpha2C2 adrenergic receptor is required for agonist- promoted phosphorylation and
10 desensitization. *Biochemistry* 1995;34:11946-11953
- Keys A: *Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease*. Cambridge, Mass, Harvard University Press, 1980
- Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, Bernstein D, Barsh GS, Kobilka BK: Cardiovascular regulation in mice lacking alpha2-adrenergic receptor
15 subtypes b and c. *Science* 1996;273:803-805
- Lomasney JW, Lorenz W, Allen LF, King K, Regan JW, Yang-Feng TL, Caron MC, Lefkowitz RJ: Expansion of the alpha-2 adrenergic receptor family: cloning and characterization of a human alpha-2 adrenergic receptor subtype, the gene for which is located on chromosome 2. *Proc Natl Acad Sci USA*. 1990;87:5094-5098.
- 20 MacDonald E, Kobilka BK, Scheinin M: Gene targeting - homing in on α_2 -adrenoceptor subtype function. *Trends Pharmacol Sci* 1997;18:211-219
- MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE: Central hypotensive effects of the alpha2a-adrenergic receptor subtype. *Science* 1996;273:801-803

Sajantila A, Salem AH, Savolainen P, Bauer K, Gierig C, Paabo S: Paternal and maternal DNA lineages reveal a bottleneck in the founding of the Finnish population. *Proc.Natl.Acad.Sci.U.S.A.* 1996;93:12035-12039

Salonen JT: Is there a continuing need for longitudinal epidemiologic research? The
5 Kuopio Ischaemic Heart Disease Risk Factor Study. *Ann.Clin Res* 1988;20:46-50

CLAIMS

1. A DNA sequence comprising a nucleotide sequence encoding a variant α_{2B} -adrenoceptor protein with a deletion of at least 1 glutamate from a glutamic acid repeat element of 12 glutamates, amino acids 298–309, in an acidic stretch of
5 18 amino acids 294–311, located in the 3rd intracellular loop of the receptor polypeptide.
2. The DNA sequence according to claim 1 comprising a nucleotide sequence encoding a variant α_{2B} -adrenoceptor protein with a deletion of 3 glutamates, amino acids 307–309, from said glutamic acid repeat element of 12 glutamates, amino
10 acids 298–309, in said acidic stretch of 18 amino acids 294–311, located in the 3rd intracellular loop of the receptor polypeptide.
3. The DNA sequence according to claim 2 comprising the genomic nucleotide sequence of SEQ ID NO: 1.
4. The DNA sequence according to claim 1 wherein said DNA sequence is
15 cDNA.
5. An RNA sequence comprising an RNA sequence corresponding to the DNA sequence of claim 1.
6. A variant α_{2B} -adrenoceptor protein having a deletion of at least 1 glutamate from said glutamic acid repeat element of 12 glutamates, amino acids 298–309, in
20 said acidic stretch of 18 amino acids 294–311, located in the 3rd intracellular loop of the receptor polypeptide.
7. A variant α_{2B} -adrenoceptor protein according to claim 6 having a deletion of 3 glutamates, amino acids 307–309, from said glutamic acid repeat element of

12 glutamates, amino acids 298–309, in said acidic stretch of 18 amino acids 294–311, located in the 3rd intracellular loop of the receptor polypeptide.

8. The variant protein according to claim 7 comprising the amino acid sequence of SEQ ID NO: 2.

5 9. An assay for determining the presence or absence of a variant gene as defined in claim 1.

10. An assay according to claim 9 wherein said assay is carried out using a gene chip, microarray, strip, panel or similar combination of more than one genes, mutations or RNA expressions to be assayed.

10 11. The assay according to claim 9 wherein the assay is a DNA-assay.

12. A method for determining the presence or absence in a biological sample of a DNA sequence as defined in claim 1, wherein said DNA, which appears in single stranded form (target nucleic acid), is brought into contact with a capturing nucleic acid probe and a detector nucleic acid probe, after which the complex "capturing
15 probe-target nucleic acid-detector probe" is detected.

13. The method according to claim 12, wherein the capturing nucleic acid probe is attached or capable of attaching to a solid phase, and comprises the cDNA sequence according to claim 4, wherein a detected signal from the solid phase is an indication of the presence in the sample of a DNA as defined in claim 1.

20 14. The method according to claim 12, wherein the capturing nucleic acid probe is attached or capable of attaching to a solid phase, and comprises the cDNA corresponding to the gene coding an α_{2B} -adrenoceptor without the deletion defined in claim 1, wherein a detected signal from the solid phase is an indication of the absence in the sample of a DNA as defined in claim 1.

15. A method for screening a subject to determine if said subject is a carrier of a said variant gene with both alleles encoding a said variant α_{2B} -adrenoceptor, i.e. to determine if said subject's genotype of the human α_{2B} -adrenoceptor is of the deletion/deletion (D/D) type, comprising the steps of
- 5 a) providing a biological sample of the subject to be screened,
 - b) providing an assay for detecting in the biological sample the presence of
 - i) the insertion/insertion (I/I) or deletion/insertion (D/I) genotypes of the human α_{2B} -adrenoceptor, or
 - ii) the D/D genotype of the human α_{2B} -adrenoceptor, and
 - 10 c) assessing at least one of the two following
 - i) an individual's risk to develop a disease involving vascular contraction of coronary arteries, or
 - ii) an individual's need for α_{2B} -selective or α_{2B} -nonselective α_2 -adrenoceptor antagonist therapy,
 - 15 based on whether said subject is of said D/D genotype or not.
16. The method according to claim 15 wherein the assay is a DNA-assay.
17. A capturing probe which comprises a single strand of the cDNA according to claim 4.
18. A capturing probe which comprises a single strand of the cDNA corresponding
- 20 to the α_{2B} -adrenoceptor without the deletion defined in claim 1
19. A method for treating a mammal suffering from vascular contraction of coronary arteries, said method comprising administering a selective α_{2B} -adrenoceptor antagonist to said mammal.

20. The method according to claim 19 wherein said mammal suffers from a disease involving said vascular contraction of coronary arteries.
21. The method according to claim 20 wherein said disease is clinically expressed as coronary heart disease or chronic angina pectoris.
- 5 22. The method according to claim 20 wherein said disease is clinically expressed as acute myocardial infarction.
23. The method according to claim 21 wherein said chronic angina pectoris is unstable.
24. The method according to claim 21 wherein said chronic angina pectoris is
10 clinically expressed as Prinzmetal's variant form.
25. A transgenic animal which carries a human DNA sequence comprising a nucleotide sequence encoding a variant α_{2B} -adrenoceptor protein with a deletion of at least 1 glutamate from a glutamic acid repeat element of 12 glutamates, amino acids 298–309, in an acidic stretch of 18 amino acids 294–311, located in the
15 3rd intracellular loop of the receptor polypeptide.
26. A transgenic animal according to claim 25 encoding a variant α_{2B} -adrenoceptor protein with a deletion of 3 glutamates, amino acids 307–309.
27. A transgenic animal which carries a human DNA sequence encoding a α_{2B} -adrenoceptor protein without said deletion of at least 1 glutamate from a
20 glutamic acid repeat element of 12 glutamates, amino acids 298–309, in an acidic stretch of 18 amino acids 294–311, located in the 3rd intracellular loop of the receptor polypeptide.

SEQUENCE LISTING

<110> Snapir, Amir
 Heinonen, Paula
 Alhopuro, Pia
 Karvonen, Matti
 Koulu, Markku
 Pesonen, Ullamari
 Scheinin, Mika
 Salonen, Jukka T
 Tuomainen, Tomi-Pekka
 Lakka, Timo A
 Nyyssönen, Kristiina
 Salonen, Riitta
 Kauhanen, Jussi
 Valkonen, Veli-Pekka

<120> A DNA molecule encoding a variant alpha-2B-adrenoceptor protein, and uses thereof

<130> Alpha-2B-AR variant

<140>

<141>

<160> 10

<170> PatentIn Ver. 2.1

<210> 1

<211> 1344

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(1341)

<223> Coding sequence for variant human
 alpha-2B-adrenoceptor protein

<400> 1
 atg gac cac cag gac ccc tac tcc gtg cag gcc aca gcg gcc ata gcg 48
 Met Asp His Gln Asp Pro Tyr Ser Val Gln Ala Thr Ala Ala Ile Ala
 1 5 10 15
 gcg gcc atc acc ttc ctc att ctc ttt acc atc ttc ggc aac gct ctg 96
 Ala Ala Ile Thr Phe Leu Ile Leu Phe Thr Ile Phe Gly Asn Ala Leu
 20 25 30
 gtc atc ctg gct gtg ttg acc agc cgc tcg ctg cgc gcc cct cag aac 144
 Val Ile Leu Ala Val Leu Thr Ser Arg Ser Leu Arg Ala Pro Gln Asn
 35 40 45
 ctg ttc ctg gtg tcg ctg gcc gcc gcc gac atc ctg gtg gcc acg ctc 192
 Leu Phe Leu Val Ser Leu Ala Ala Ala Asp Ile Leu Val Ala Thr Leu
 50 55 60
 atc atc cct ttc tcg ctg gcc aac gag ctg ctg ggc tac tgg tac ttc 240
 Ile Ile Pro Phe Ser Leu Ala Asn Glu Leu Leu Gly Tyr Trp Tyr Phe
 65 70 75 80
 cgg cgc acg tgg tgc gag gtg tac ctg gcg ctc gac gtg ctc ttc tgc 288
 Arg Arg Thr Trp Cys Glu Val Tyr Leu Ala Leu Asp Val Leu Phe Cys
 85 90 95

acc	tcg	tcc	atc	gtg	cac	ctg	tgc	gcc	atc	agc	ctg	gac	cgc	tac	tgg	336
Thr	Ser	Ser	Ile	Val	His	Leu	Cys	Ala	Ile	Ser	Leu	Asp	Arg	Tyr	Trp	
			100					105					110			
gcc	gtg	agc	cgc	gcg	ctg	gag	tac	aac	tcc	aag	cgc	acc	ccg	cgc	cgc	384
Ala	Val	Ser	Arg	Ala	Leu	Glu	Tyr	Asn	Ser	Lys	Arg	Thr	Pro	Arg	Arg	
		115					120					125				
atc	aag	tgc	atc	atc	ctc	act	gtg	tgg	ctc	atc	gcc	gcc	gtc	atc	tcg	432
Ile	Lys	Cys	Ile	Ile	Leu	Thr	Val	Trp	Leu	Ile	Ala	Ala	Val	Ile	Ser	
	130					135					140					
ctg	ccg	ccc	ctc	atc	tac	aag	ggc	gac	cag	ggc	ccc	cag	ccg	cgc	ggg	480
Leu	Pro	Pro	Leu	Ile	Tyr	Lys	Gly	Asp	Gln	Gly	Pro	Gln	Pro	Arg	Gly	
	145				150					155					160	
cgc	ccc	cag	tgc	aag	ctc	aac	cag	gag	gcc	tgg	tac	atc	ctg	gcc	tcc	528
Arg	Pro	Gln	Cys	Lys	Leu	Asn	Gln	Glu	Ala	Trp	Tyr	Ile	Leu	Ala	Ser	
				165					170					175		
agc	atc	gga	tct	ttc	ttt	gct	cct	tgc	ctc	atc	atg	atc	ctt	gtc	tac	576
Ser	Ile	Gly	Ser	Phe	Phe	Ala	Pro	Cys	Leu	Ile	Met	Ile	Leu	Val	Tyr	
			180					185					190			
ctg	cgc	atc	tac	ctg	atc	gcc	aaa	cgc	agc	aac	cgc	aga	ggc	ccc	agg	624
Leu	Arg	Ile	Tyr	Leu	Ile	Ala	Lys	Arg	Ser	Asn	Arg	Arg	Gly	Pro	Arg	
		195					200					205				
gcc	aag	ggg	ggg	cct	ggg	cag	ggc	gag	tcc	aag	cag	ccc	cga	ccc	gac	672
Ala	Lys	Gly	Gly	Pro	Gly	Gln	Gly	Glu	Ser	Lys	Gln	Pro	Arg	Pro	Asp	
	210					215					220					
cat	ggc	ggg	gct	ttg	gcc	tca	gcc	aaa	ctg	cca	gcc	ctg	gcc	tct	gtg	720
His	Gly	Gly	Ala	Leu	Ala	Ser	Ala	Lys	Leu	Pro	Ala	Leu	Ala	Ser	Val	
	225				230					235					240	
gct	tct	gcc	aga	gag	gtc	aac	gga	cac	tcg	aag	tcc	act	ggg	gag	aag	768
Ala	Ser	Ala	Arg	Glu	Val	Asn	Gly	His	Ser	Lys	Ser	Thr	Gly	Glu	Lys	
				245					250					255		
gag	gag	ggg	gag	acc	cct	gaa	gat	act	ggg	acc	cgg	gcc	ttg	cca	ccc	816
Glu	Glu	Gly	Glu	Thr	Pro	Glu	Asp	Thr	Gly	Thr	Arg	Ala	Leu	Pro	Pro	
			260					265					270			
agt	tgg	gct	gcc	ctt	ccc	aac	tca	ggc	cag	ggc	cag	aag	gag	ggc	gtt	864
Ser	Trp	Ala	Ala	Leu	Pro	Asn	Ser	Gly	Gln	Gly	Gln	Lys	Glu	Gly	Val	
		275					280					285				
tgt	ggg	gca	tct	cca	gag	gat	gaa	gct	gaa	gag	gag	gaa	gag	gag	gag	912
Cys	Gly	Ala	Ser	Pro	Glu	Asp	Glu	Ala	Glu	Glu	Glu	Glu	Glu	Glu	Glu	
	290					295					300					
gag	gag	tgt	gaa	ccc	cag	gca	gtg	cca	gtg	tct	ccg	gcc	tca	gct	tgc	960
Glu	Glu	Cys	Glu	Pro	Gln	Ala	Val	Pro	Val	Ser	Pro	Ala	Ser	Ala	Cys	
	305				310					315					320	
agc	ccc	ccg	ctg	cag	cag	cca	cag	ggc	tcc	cgg	gtg	ctg	gcc	acc	cta	1008
Ser	Pro	Pro	Leu	Gln	Gln	Pro	Gln	Gly	Ser	Arg	Val	Leu	Ala	Thr	Leu	
				325					330					335		
cgt	ggc	cag	gtg	ctc	ctg	ggc	agg	ggc	gtg	ggc	gct	ata	ggc	ggg	cag	1056
Arg	Gly	Gln	Val	Leu	Leu	Gly	Arg	Gly	Val	Gly	Ala	Ile	Gly	Gly	Gln	
			340					345					350			

tgg tgg cgt cga cgg gcg cag ctg acc cgg gag aag cgc ttc acc ttc 1104
 Trp Trp Arg Arg Arg Ala Gln Leu Thr Arg Glu Lys Arg Phe Thr Phe
 355 360 365
 gtg ctg gct gtg gtc att ggc gtt ttt gtg ctc tgc tgg ttc ccc ttc 1152
 Val Leu Ala Val Val Ile Gly Val Phe Val Leu Cys Trp Phe Pro Phe
 370 375 380
 ttc ttc agc tac agc ctg ggc gcc atc tgc ccg aag cac tgc aag gtg 1200
 Phe Phe Ser Tyr Ser Leu Gly Ala Ile Cys Pro Lys His Cys Lys Val
 385 390 395 400
 ccc cat ggc ctc ttc cag ttc ttc ttc tgg atc ggc tac tgc aac agc 1248
 Pro His Gly Leu Phe Gln Phe Phe Phe Trp Ile Gly Tyr Cys Asn Ser
 405 410 415
 tca ctg aac cct gtt atc tac acc atc ttc aac cag gac ttc cgc cgt 1296
 Ser Leu Asn Pro Val Ile Tyr Thr Ile Phe Asn Gln Asp Phe Arg Arg
 420 425 430
 gcc ttc cgg agg atc ctg tgc cgc ccg tgg acc cag acg gcc tgg tga 1344
 Ala Phe Arg Arg Ile Leu Cys Arg Pro Trp Thr Gln Thr Ala Trp
 435 440 445

<210> 2
 <211> 447
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Asp His Gln Asp Pro Tyr Ser Val Gln Ala Thr Ala Ala Ile Ala
 1 5 10 15
 Ala Ala Ile Thr Phe Leu Ile Leu Phe Thr Ile Phe Gly Asn Ala Leu
 20 25 30
 Val Ile Leu Ala Val Leu Thr Ser Arg Ser Leu Arg Ala Pro Gln Asn
 35 40 45
 Leu Phe Leu Val Ser Leu Ala Ala Ala Asp Ile Leu Val Ala Thr Leu
 50 55 60
 Ile Ile Pro Phe Ser Leu Ala Asn Glu Leu Leu Gly Tyr Trp Tyr Phe
 65 70 75 80
 Arg Arg Thr Trp Cys Glu Val Tyr Leu Ala Leu Asp Val Leu Phe Cys
 85 90 95
 Thr Ser Ser Ile Val His Leu Cys Ala Ile Ser Leu Asp Arg Tyr Trp
 100 105 110
 Ala Val Ser Arg Ala Leu Glu Tyr Asn Ser Lys Arg Thr Pro Arg Arg
 115 120 125
 Ile Lys Cys Ile Ile Leu Thr Val Trp Leu Ile Ala Ala Val Ile Ser
 130 135 140
 Leu Pro Pro Leu Ile Tyr Lys Gly Asp Gln Gly Pro Gln Pro Arg Gly
 145 150 155 160
 Arg Pro Gln Cys Lys Leu Asn Gln Glu Ala Trp Tyr Ile Leu Ala Ser
 165 170 175
 Ser Ile Gly Ser Phe Phe Ala Pro Cys Leu Ile Met Ile Leu Val Tyr
 180 185 190


```

Leu Arg Ile Tyr Leu Ile Ala Lys Arg Ser Asn Arg Arg Gly Pro Arg
    195                                200                                205
Ala Lys Gly Gly Pro Gly Gln Gly Glu Ser Lys Gln Pro Arg Pro Asp
    210                                215                                220
His Gly Gly Ala Leu Ala Ser Ala Lys Leu Pro Ala Leu Ala Ser Val
    225                                230                                235                                240
Ala Ser Ala Arg Glu Val Asn Gly His Ser Lys Ser Thr Gly Glu Lys
    245                                250                                255
Glu Glu Gly Glu Thr Pro Glu Asp Thr Gly Thr Arg Ala Leu Pro Pro
    260                                265                                270
Ser Trp Ala Ala Leu Pro Asn Ser Gly Gln Gly Gln Lys Glu Gly Val
    275                                280                                285
Cys Gly Ala Ser Pro Glu Asp Glu Ala Glu Glu Glu Glu Glu Glu
    290                                295                                300
Glu Glu Cys Glu Pro Gln Ala Val Pro Val Ser Pro Ala Ser Ala Cys
    305                                310                                315                                320
Ser Pro Pro Leu Gln Gln Pro Gln Gly Ser Arg Val Leu Ala Thr Leu
    325                                330                                335
Arg Gly Gln Val Leu Leu Gly Arg Gly Val Gly Ala Ile Gly Gly Gln
    340                                345                                350
Trp Trp Arg Arg Arg Ala Gln Leu Thr Arg Glu Lys Arg Phe Thr Phe
    355                                360                                365
Val Leu Ala Val Val Ile Gly Val Phe Val Leu Cys Trp Phe Pro Phe
    370                                375                                380
Phe Phe Ser Tyr Ser Leu Gly Ala Ile Cys Pro Lys His Cys Lys Val
    385                                390                                395                                400
Pro His Gly Leu Phe Gln Phe Phe Phe Trp Ile Gly Tyr Cys Asn Ser
    405                                410                                415
Ser Leu Asn Pro Val Ile Tyr Thr Ile Phe Asn Gln Asp Phe Arg Arg
    420                                425                                430
Ala Phe Arg Arg Ile Leu Cys Arg Pro Trp Thr Gln Thr Ala Trp
    435                                440                                445

```

```

<210> 3
<211> 1353
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> CDS
<222> (1)..(1350)
<223> Coding sequence for human alpha-2B-adrenoceptor
        protein

```

```

<400> 3
atg gac cac cag gac ccc tac tcc gtg cag gcc aca gcg gcc ata gcg      48
Met Asp His Gln Asp Pro Tyr Ser Val Gln Ala Thr Ala Ala Ile Ala
  1                                5                                10                                15

```

gcg gcc atc acc ttc ctc att ctc ttt acc atc ttc ggc aac gct ctg	96
Ala Ala Ile Thr Phe Leu Ile Leu Phe Thr Ile Phe Gly Asn Ala Leu	
20 25 30	
gtc atc ctg gct gtg ttg acc agc cgc tcg ctg cgc gcc cct cag aac	144
Val Ile Leu Ala Val Leu Thr Ser Arg Ser Leu Arg Ala Pro Gln Asn	
35 40 45	
ctg ttc ctg gtg tcg ctg gcc gcc gcc gac atc ctg gtg gcc acg ctc	192
Leu Phe Leu Val Ser Leu Ala Ala Ala Asp Ile Leu Val Ala Thr Leu	
50 55 60	
atc atc cct ttc tcg ctg gcc aac gag ctg ctg ggc tac tgg tac ttc	240
Ile Ile Pro Phe Ser Leu Ala Asn Glu Leu Leu Gly Tyr Trp Tyr Phe	
65 70 75 80	
cgg cgc acg tgg tgc gag gtg tac ctg gcg ctc gac gtg ctc ttc tgc	288
Arg Arg Thr Trp Cys Glu Val Tyr Leu Ala Leu Asp Val Leu Phe Cys	
85 90 95	
acc tcg tcc atc gtg cac ctg tgc gcc atc agc ctg gac cgc tac tgg	336
Thr Ser Ser Ile Val His Leu Cys Ala Ile Ser Leu Asp Arg Tyr Trp	
100 105 110	
gcc gtg agc cgc gcg ctg gag tac aac tcc aag cgc acc ccg cgc cgc	384
Ala Val Ser Arg Ala Leu Glu Tyr Asn Ser Lys Arg Thr Pro Arg Arg	
115 120 125	
atc aag tgc atc atc ctc act gtg tgg ctc atc gcc gcc gtc atc tcg	432
Ile Lys Cys Ile Ile Leu Thr Val Trp Leu Ile Ala Ala Val Ile Ser	
130 135 140	
ctg ccg ccc ctc atc tac aag ggc gac cag ggc ccc cag ccg cgc ggg	480
Leu Pro Pro Leu Ile Tyr Lys Gly Asp Gln Gly Pro Gln Pro Arg Gly	
145 150 155 160	
cgc ccc cag tgc aag ctc aac cag gag gcc tgg tac atc ctg gcc tcc	528
Arg Pro Gln Cys Lys Leu Asn Gln Glu Ala Trp Tyr Ile Leu Ala Ser	
165 170 175	
agc atc gga tct ttc ttt gct cct tgc ctc atc atg atc ctt gtc tac	576
Ser Ile Gly Ser Phe Phe Ala Pro Cys Leu Ile Met Ile Leu Val Tyr	
180 185 190	
ctg cgc atc tac ctg atc gcc aaa cgc agc aac cgc aga ggt ccc agg	624
Leu Arg Ile Tyr Leu Ile Ala Lys Arg Ser Asn Arg Arg Gly Pro Arg	
195 200 205	
gcc aag ggg ggg cct ggg cag ggt gag tcc aag cag ccc cga ccc gac	672
Ala Lys Gly Gly Pro Gly Gln Gly Glu Ser Lys Gln Pro Arg Pro Asp	
210 215 220	
cat ggt ggg gct ttg gcc tca gcc aaa ctg cca gcc ctg gcc tct gtg	720
His Gly Gly Ala Leu Ala Ser Ala Lys Leu Pro Ala Leu Ala Ser Val	
225 230 235 240	
gct tct gcc aga gag gtc aac gga cac tcg aag tcc act ggg gag aag	768
Ala Ser Ala Arg Glu Val Asn Gly His Ser Lys Ser Thr Gly Glu Lys	
245 250 255	
gag gag ggg gag acc cct gaa gat act ggg acc cgg gcc ttg cca ccc	816
Glu Glu Gly Glu Thr Pro Glu Asp Thr Gly Thr Arg Ala Leu Pro Pro	
260 265 270	

```

    agt tgg gct gcc ctt ccc aac tca ggc cag ggc cag aag gag ggt gtt 864
    Ser Trp Ala Ala Leu Pro Asn Ser Gly Gln Gly Gln Lys Glu Gly Val
        275                280                285

    tgt ggg gca tct cca gag gat gaa gct gaa gag gag gaa gag gag gag 912
    Cys Gly Ala Ser Pro Glu Asp Glu Ala Glu Glu Glu Glu Glu Glu
        290                295                300

    gag gag gag gaa gag tgt gaa ccc cag gca gtg cca gtg tct ccg gcc 960
    Glu Glu Glu Glu Glu Cys Glu Pro Gln Ala Val Pro Val Ser Pro Ala
    305                310                315                320

    tca gct tgc agc ccc ccg ctg cag cag cca cag ggc tcc cgg gtg ctg 1008
    Ser Ala Cys Ser Pro Pro Leu Gln Gln Pro Gln Gly Ser Arg Val Leu
        325                330                335

    gcc acc cta cgt ggc cag gtg ctc ctg ggc agg ggc gtg ggt gct ata 1056
    Ala Thr Leu Arg Gly Gln Val Leu Leu Gly Arg Gly Val Gly Ala Ile
        340                345                350

    ggt ggg cag tgg tgg cgt cga cgg gcg cag ctg acc cgg gag aag cgc 1104
    Gly Gly Gln Trp Trp Arg Arg Arg Ala Gln Leu Thr Arg Glu Lys Arg
        355                360                365

    ttc acc ttc gtg ctg gct gtg gtc att ggc gtt ttt gtg ctc tgc tgg 1152
    Phe Thr Phe Val Leu Ala Val Val Ile Gly Val Phe Val Leu Cys Trp
        370                375                380

    ttc ccc ttc ttc ttc agc tac agc ctg ggc gcc atc tgc ccg aag cac 1200
    Phe Pro Phe Phe Phe Ser Tyr Ser Leu Gly Ala Ile Cys Pro Lys His
    385                390                395                400

    tgc aag gtg ccc cat ggc ctc ttc cag ttc ttc ttc tgg atc ggc tac 1248
    Cys Lys Val Pro His Gly Leu Phe Gln Phe Phe Phe Trp Ile Gly Tyr
        405                410                415

    tgc aac agc tca ctg aac cct gtt atc tac acc atc ttc aac cag gac 1296
    Cys Asn Ser Ser Leu Asn Pro Val Ile Tyr Thr Ile Phe Asn Gln Asp
        420                425                430

    ttc cgc cgt gcc ttc cgg agg atc ctg tgc cgc ccg tgg acc cag acg 1344
    Phe Arg Arg Ala Phe Arg Arg Ile Leu Cys Arg Pro Trp Thr Gln Thr
        435                440                445

    gcc tgg tga
    Ala Trp
        450

```

```

<210> 4
<211> 450
<212> PRT
<213> Homo sapiens

```

```

<400> 4
Met Asp His Gln Asp Pro Tyr Ser Val Gln Ala Thr Ala Ala Ile Ala
  1          5          10          15

Ala Ala Ile Thr Phe Leu Ile Leu Phe Thr Ile Phe Gly Asn Ala Leu
  20          25          30

Val Ile Leu Ala Val Leu Thr Ser Arg Ser Leu Arg Ala Pro Gln Asn
  35          40          45

Leu Phe Leu Val Ser Leu Ala Ala Ala Asp Ile Leu Val Ala Thr Leu
  50          55          60

```

Ile Ile Pro Phe Ser Leu Ala Asn Glu Leu Leu Gly Tyr Trp Tyr Phe
 65 70 75 80
 Arg Arg Thr Trp Cys Glu Val Tyr Leu Ala Leu Asp Val Leu Phe Cys
 85 90 95
 Thr Ser Ser Ile Val His Leu Cys Ala Ile Ser Leu Asp Arg Tyr Trp
 100 105 110
 Ala Val Ser Arg Ala Leu Glu Tyr Asn Ser Lys Arg Thr Pro Arg Arg
 115 120 125
 Ile Lys Cys Ile Ile Leu Thr Val Trp Leu Ile Ala Ala Val Ile Ser
 130 135 140
 Leu Pro Pro Leu Ile Tyr Lys Gly Asp Gln Gly Pro Gln Pro Arg Gly
 145 150 155 160
 Arg Pro Gln Cys Lys Leu Asn Gln Glu Ala Trp Tyr Ile Leu Ala Ser
 165 170 175
 Ser Ile Gly Ser Phe Phe Ala Pro Cys Leu Ile Met Ile Leu Val Tyr
 180 185 190
 Leu Arg Ile Tyr Leu Ile Ala Lys Arg Ser Asn Arg Arg Gly Pro Arg
 195 200 205
 Ala Lys Gly Gly Pro Gly Gln Gly Glu Ser Lys Gln Pro Arg Pro Asp
 210 215 220
 His Gly Gly Ala Leu Ala Ser Ala Lys Leu Pro Ala Leu Ala Ser Val
 225 230 235 240
 Ala Ser Ala Arg Glu Val Asn Gly His Ser Lys Ser Thr Gly Glu Lys
 245 250 255
 Glu Glu Gly Glu Thr Pro Glu Asp Thr Gly Thr Arg Ala Leu Pro Pro
 260 265 270
 Ser Trp Ala Ala Leu Pro Asn Ser Gly Gln Gly Gln Lys Glu Gly Val
 275 280 285
 Cys Gly Ala Ser Pro Glu Asp Glu Ala Glu Glu Glu Glu Glu Glu
 290 295 300
 Glu Glu Glu Glu Glu Cys Glu Pro Gln Ala Val Pro Val Ser Pro Ala
 305 310 315 320
 Ser Ala Cys Ser Pro Pro Leu Gln Gln Pro Gln Gly Ser Arg Val Leu
 325 330 335
 Ala Thr Leu Arg Gly Gln Val Leu Leu Gly Arg Gly Val Gly Ala Ile
 340 345 350
 Gly Gly Gln Trp Trp Arg Arg Arg Ala Gln Leu Thr Arg Glu Lys Arg
 355 360 365
 Phe Thr Phe Val Leu Ala Val Val Ile Gly Val Phe Val Leu Cys Trp
 370 375 380
 Phe Pro Phe Phe Phe Ser Tyr Ser Leu Gly Ala Ile Cys Pro Lys His
 385 390 395 400
 Cys Lys Val Pro His Gly Leu Phe Gln Phe Phe Phe Trp Ile Gly Tyr
 405 410 415

Cys Asn Ser Ser Leu Asn Pro Val Ile Tyr Thr Ile Phe Asn Gln Asp
 420 425 430
 Phe Arg Arg Ala Phe Arg Arg Ile Leu Cys Arg Pro Trp Thr Gln Thr
 435 440 445
 Ala Trp
 450

<210> 5
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: PCR primer
 pair

<400> 5
 ggggcgacgc tcttgtcta

19

<210> 6
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: PCR primer
 pair

<400> 6
 ggtctccccc tcctccttc

19

<210> 7
 <211> 18
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: PCR primer
 pair

<400> 7
 gcagcaaccg cagaggtc

18

<210> 8
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: PCR primer
 pair

<400> 8
 gggcaagaag cagggtgac

19

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer
pair

<400> 9
agggtgtttg tggggcatct

20

<210> 10
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer
pair

<400> 10
caagctgagg ccggagacac t

21

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 00/00913

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07K 14/47, C07K 14/72

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	The Journal of Clinical Endocrinology & Metabolism, Volume 84, No 7, 1999, PAULA HEINONEN et al, "Identification of a Three-Amino Acid Deletion in the Adrenergic Receptor That Is Associated with Reduced Basal Metabolic Rate in Obese Subjects", page 2430, column 2, line 33 - line 39, figures 1,2, page 2429 - 2433	1-18
Y	--	19-27
X	US 5595880 A (RICHARD L. WEINSHANK ET AL), 21 January 1997 (21.01.97), column 2, line 46 - column 3, line 19, figure 2	18
A	--	1-17, 19-24

☒ Further documents are listed in the continuation of Box C.
☒ See patent family annex.

<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>
---	---

Date of the actual completion of the international search	Date of mailing of the international search report
28 February 2001	01 -03- 2001
Name and mailing address of the ISA: Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86	Authorized officer Frida Plym Forsshell/mj Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 00/00913

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	J Am Coll Cardiol, Volume 33, No 6, 1999, Julius BK, "Alpha-adrenoceptor blockade prevents exercise-induced vasoconstriction of stenotic coronary arteries" page 1499 - page 1505 --	19-24
Y	US 5861309 A (JONATHAN A. BARD ET AL), 19 March 1999 (19.03.99), column 4, line 35 - line 54 -- -----	25-27

INTERNATIONAL SEARCH REPORT

International application No.
PCT/FI00/00913

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

see extra sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 00/00913

Claims 15 and 16 relate to a diagnostic method practised on the human or animal body, and claims 19 -24 relate to a method for treatment of the human or animal body by therapy. Thus, the International Search Authority is not required to carry out an international search for these claims (Rule 39.1(iv)). Nevertheless, a search has been executed for claims 15,16 and 19-24.

INTERNATIONAL SEARCH REPORT
Information on patent family members

05/02/01

International application No.
PCT/FI 00/00913

Patent document cited in search report			Publication date	Patent family member(s)			Publication date
US	5595880	A	21/01/97	US	5053337	A	01/10/91
US	5861309	A	19/03/99	AU	677968	B	15/05/97
				AU	5165693	A	26/04/94
				DE	663014	T	10/10/96
				EP	0663014	A	19/07/95
				GR	95300067	T	31/01/96
				JP	8505044	T	04/06/96
				AU	718197	B	06/04/00
				AU	3420797	A	29/01/98
				CA	2145182	A	14/04/94
				EP	1063291	A	27/12/00
				EP	1063292	A	27/12/00
				ES	2085247	T	01/06/96
				US	5556753	A	17/09/96
				US	5714381	A	03/02/98
				US	6083705	A	04/07/00
				US	6156518	A	05/12/00
				WO	9408040	A	14/04/94

